High frequency of immunophenotype changes in acute myeloid leukemia at relapse: Implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

Blood

Volumn 97, Issue 11, 2001, Pages 3574-3580

  Baer, Maria R ^{a,b,c,d,e,f,g,h,i,j,k,l}   Stewart, Carleton C ^{a,b,c,d,e,f,g,h,i,j,k,l}   Dodgé, Richard K ^{a,b,c,d,e,f,g,h,i,j,k,l}   Leget, Gail ^{a,b,c,d,e,f,g,h,i,j,k,l}   Suie, Norbert ^{a,b,c,d,e,f,g,h,i,j,k,l}   Mrózek, Krzysztof ^{a,b,c,d,e,f,g,h,i,j,k,l}   Schiffer, Charles A ^{a,b,c,d,e,f,g,h,i,j,k,l}   Powell, Bayard L ^{a,b,c,d,e,f,g,h,i,j,k,l}   Kolitz, Jonathan E ^{a,b,c,d,e,f,g,h,i,j,k,l}   Moore, Joseph O ^{a,b,c,d,e,f,g,h,i,j,k,l}   Stone, Richard M ^{a,b,c,d,e,f,g,h,i,j,k,l}   Davey, Frederick R ^{a,b,c,d,e,f,g,h,i,j,k,l}   Carroll, Andrew J ^{a,b,c,d,e,f,g,h,i,j,k,l}   Larson, Richard A ^{a,b,c,d,e,f,g,h,i,j,k,l}   Bloomfield, Clara D ^{a,b,c,d,e,f,g,h,i,j,k,l}  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CALGB Statistical Center   (United States)

^c Southeastern Cancer Center   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL;

EID: 0035383779     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3574     Document Type: Article

References (43)

1. Stewart CC, Clinical applications of flow cytometry: immunologic methods for measuring cell membrane and cytoplasmic antigens. Cancer, 1992;69(suppl 1):1543-1552.
2. Terstappen LWMM, Safford M, Könemann S, et al. Flow cytometric characterization of acute myeloid leukemia, II: phenotypic heterogeneity at diagnosis. Leukemia. 1992;6:70-80.
3. Reading CL, Estey EH, Huh YO, et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood. 1993;81: 3083-3090.
4. San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients, Blood. 1997;90:2465-2470.
5. Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8364, Blood. 1999;93: 3931-3939.
6. Stone RM, Berg DT, George SL, et al. Granulecyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med. 1995;332:1671-1677.
7. Moore JO, Dodge RK, Amrein PC, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood. 1997;89:780-788.
8. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
9. Moore JO, Powell B, Veiez-Garcia E, et al. A comparison of sequential non-cross-resistant therapy or Ara-C consolidation following complete remission in adult patients >60 years with acute myeloid leukemia: CALGB 9222. Proc. Am Soc Clin Oncol. 1997;16:14a.
10. Lee EJ, George SL, Caligiuri M, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B Study 9420. J Clin Oncol. 1999;17:2831-2839.
11. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
12. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol. 1991;78:325-329.
13. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8: 813-819.
14. Mitelman F. ISCN: an International System for Human Cytogenetic Nomenclature. Basel, Switzerland; Karger; 1995.
15. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22; q22). Blood. 1997;90:1643-1648.
16. Baer MR, Stewart CC, Lawrence D, et al. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia. 1998;12:317-325.
17. Riedy MC, Muirhead KA, Jensen CP, Stewart CC. Use of a photolabeling technique to identify nonviable cells in fixed homologous or heterologous cell populations. Cytometry. 1991;12:133-139.
18. National Committee for Clinical Laboratory Standards. Clinical applications of flow cytometry: immunophenotyping of leukemic cells; proposed guidelines. Document H43-P, Villanova, PA: Author; 1993.
19. Agresti A. Categorical Data Analysis. New York, NY: Wiley; 1990.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:475-481.
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
22. Macedo A, Odao A, Viddales MB, et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol. 1995;70:189-194.
23. Macedo A, Orfao A, Gonzalez M, et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia. 1995;9:993-998.
24. Thomas X, Campos L, Archimbaud E, et al. Surface marker expression in acute myeloid leukaemia at first relapse. Br J Haematol. 1992;81:40-44.
25. Drach J, Drach D, Glassl H, Gattringer C, Huber H. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry. 1992;13: 893-901.
26. Macedo A, San Miguel JF, Vidriales MB, et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol. 1996;49:15-16.
27. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38:139-152.
28. Estey E, Keating MJ, Pierce S, Stass S. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia. 1995; 9:972-976.
29. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992;79:473-476.
30. Guerci A, Merlin JL, Missoum N, et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicih accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood. 1995;85:2147-2153.
31. Chaudhary PM, Roninson IB, Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991;66:85-94.
32. Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M. Flow Cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry. 1994;17:84-93.
33. Hart SM, Ganeshaguru K, Scheper RJ, Prentice HG, Hoffbrand AV, Mehta AB. Expression of the human major vault protein LRP in acute myeloid leukemia. Exp Hematol. 1997;25:1227-1232.
34. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia. 1994;8:2163-2168.
35. Schneider E, Cowan KH, Bader H, et al. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood. 1995;85:186-193.
36. Zhou D-C, Zittoun R, Marie J-P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia. 1995;9:1661-1666.
37. Bailly J-D, Muller C, Jaffrezou J-P, et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia. 1995;9:799-807.
38. + acute myeloid leukemia cells. Blood. 1993;82:3157-3162.
39. Leith CP, Chen I-M, Kopecky KJ, et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1 + /efflux - cases. Blood. 1995;86: 2329-2342.
40. List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 1996;87:2464-2469.
41. Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM 195 in myelogenous leukemia. Clin Cancer Res. 1998;4:1421-1428.
42. Pagliaro LC, Liu B, Munker R, et al. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin Cancer Res. 1998;4: 1971-1976.
43. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.